FDC Limited
FDC · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹492.31.
Piotroski F-score 5/9 — quality of earnings & balance sheet.
Investability checklist
- ✕ROE above 15%11.8%
- ✓Low debt (D/E < 0.5)0.01x
- ✕Positive free cash flow
- ✓Revenue growth > 10%19%
- ✓Earnings growing167%
- ✓Net margin ≥ 10%13.0%
- ✓Current ratio > 1.53.11
- ✓Below our fair value
- ✓Margin of safety ≥ 20%
- ✕Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 10.42
- ✕Piotroski ≥ 75/9
1-year price
EOD · 2026-06-16Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Quarterly results
Annual financials
Shareholding
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
- •Financially solid — Altman Z 10.42.
Weaknesses
- •Price below its 200-day moving average (downtrend).
Opportunities
- •Earnings growing (167% YoY).
- •Revenue growing (19% YoY).
- •Trading in our value buy zone versus sector peers.
- •Trades ~60% below our estimated fair value.
About FDC Limited
FDC Limited, together with its subsidiaries, manufactures and trades in pharmaceutical products in India, the United States, and internationally. The company offers pharmaceutical formulations for various therapeutic segments, including anti-infectives, gastrointestinal, ophthalmology, vitamins, minerals, dietary supplements, cardiovascular and anti-diabetic therapies, respiratory care, gynaecology, dermatology, and analgesics in the form of tablets, capsules, oral liquids, o
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.